

CLAIMS

- [1] A cancer gene therapeutic drug including a carrier cell to be infected with an oncolytic virus, so as to make the oncolytic virus act on a tumor cell within a living body, wherein the carrier cell is selected from the following (1) to (4) cells:
 - (1) A549 cell
 - (2) 293 cell
 - (3) SW626 cell, and
 - (4) HT-3 cell.
- [2] The cancer gene therapeutic drug according to claim 1, wherein the oncolytic virus to be infected to the carrier cell has 1A1.3B promoter, midkine promoter, β -HCG promoter, SCCA1 promoter, cox-2 promoter, PSA promoter or another tumor specific promoter, according to a kind of cancer to be treated etc.
- [3] The cancer gene therapeutic drug according to claim 1 or 2, wherein the oncolytic virus is selected from adenovirus, herpes virus, lentivirus such as HIV virus, retrovirus, reovirus, vesicular stomatitis virus (VSV) and any other oncolytic viruses.
- [4] The cancer gene therapeutic drug according to claim 1, further comprising a virus for immunological treatment to be administered for inducing a CTL reaction within the living body to administration of the carrier cell.
- [5] The cancer gene therapeutic drug according to claim 1, further comprising atelocollagen.
- [6] The cancer gene therapeutic drug according to claim 1, further comprising a GM-CSF expression vector to be infected to the carrier cell before administration.
- [7] The cancer gene therapeutic drug according to claim 1, further comprising an iron preparation and/or a porphyrin compound.

- [8] The cancer gene therapeutic drug according to claim 1, further comprising a tumor cell to be administered for tumor vaccination.